A systemic application of EGFR inhibitors, e.g. during lung cancer therapy, is frequently accompanied by cutaneous adverse effects, including an acceleration of keratinocyte differentiation and an impairment of the epidermal barrier (Lacouture, 2006; Lichtenberger et al., 2013). The gene discussed is EGFR; the disease is lung carcinoma.